Seneca provides further support to Optibiotix

Seneca provides further support to Optibiotix

A York life sciences business developing products to tackle obesity, high cholesterol and diabetes has raised £1m of funding in a placing which has led to Seneca Partners increasing its stake.

Stephen O’Hara, chief executive of OptiBiotix, said: “We are delighted that Seneca, as a major shareholder and respected wealth manager, have increased their stake in OptiBiotix. The funds will be used to further accelerate our development programmes to capitalise on the growing number of opportunities arising in the rapidly evolving microbiome space and build shareholder value.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.